Epstein-Barr Virus as a Promising Immunotherapeutic Target for Nasopharyngeal Carcinoma Treatment. (31st December 2017)

• Record Type: Journal Article
• Authors: Teow, Sin-Yeang; Yap, Hooi-Yeen; Peh, Suat-Cheng
• Other Names: D'Elios Mario M. Academic Editor.
• Is Part Of: Journal of pathogens. Volume 2017(2017)
• Publication Date: 2017-12-31
• Subjects: Pathogenic microorganisms -- Periodicals; Bacteria -- pathogenicity; Microbiological Phenomena; Infection; Pathogenic microorganisms; Electronic journals; Periodicals; Periodicals; Fulltext; Internet Resources; Periodicals; 616.9
• DOI: 10.1155/2017/7349268
• Languages: English
• ISSNs: 2090-3057

Abstract

Abstract : Epstein-Barr virus (EBV) is a pathogen that infects more than 90% of global human population. EBV primarily targets B-lymphocytes and epithelial cells while some of them infect monocyte/macrophage, T-lymphocytes, and dendritic cells (DCs). EBV infection does not cause death by itself but the infection has been persistently associated with certain type of cancers such as nasopharyngeal carcinoma (NPC), Burkitt's lymphoma (BL), and Hodgkin's lymphoma (HL). Recent findings have shown promise on targeting EBV proteins for cancer therapy by immunotherapeutic approach. Some studies have also shown the success of adopting EBV-based therapeutic vaccines for the prevention of EBV-associated cancer particularly on NPC. In-depth investigations are in progress to refine the current therapeutic and vaccination strategies. In present review, we discuss the highly potential EBV targets for NPC immunotherapy and therapeutic vaccine development as well as addressing the underlying challenges in the process of bringing the therapy and vaccination from the bench to bedside.